A multicentered investigator-initiated Phase 2 study in patients with RTHβ
Latest Information Update: 10 Dec 2024
Price :
$35 *
At a glance
- Drugs Tiratricol (Primary)
- Indications Allan-Herndon-Dudley syndrome
- Focus Therapeutic Use
- 10 Dec 2024 New trial record
- 04 Dec 2024 According to Egetis Therapeutics media release, the Company is contemplating to support a multicentered investigator initiated Phase 2 study in patients with RTHB in collaboration with academia.